

Table 2. Influence of Chol in the stability of the formulations developed by FM and incubated at 37°C with culture cell medium. Data represent the mean of three independent measurements with SD in parentheses.

	Time (h)	Size (nm)	PDI	Zeta potencial (mV)	ED (%)
HSPC-PEG ₂₀₀₀	0	91.5 (0.4)	0.190 (0.03)	-17.2 (1.6)	100
HSPC-Chol-PEG ₂₀₀₀	0	122.9 (2.1)	0.050 (0.03)	-22.2 (1.0)	100
COMPLETE MEDIUM					
HSPC-PEG ₂₀₀₀	1	74.1 (1.7)	0.203 (0.01)	-14.0 (0.7)	86.2 (0.15)
HSPC-Chol-PEG ₂₀₀₀	1	118.6 (1.8)	0.081 (0.01)	-21.7 (1.3)	95.0 (0.01)
HSPC-PEG ₂₀₀₀	4	73.7 (0.5)	0.231 (0.02)	-11.8 (2.0)	79.1 (0.01)
HSPC-Chol-PEG ₂₀₀₀	4	116.7 (0.5)	0.098 (0.05)	-20.7 (1.6)	87.9 (0.01)
HSPC-PEG ₂₀₀₀	7	76.1 (0.7)	0.248 (0.02)	-12.6 (1.1)	72.2 (0.01)
HSPC-Chol-PEG ₂₀₀₀	7	115. (0.6)	0.103 (0.01)	-23.2 (1.4)	78.9 (0.01)
HSPC-PEG ₂₀₀₀	24	82.1 (1.3)	0.250 (0.01)	-11.6 (1.2)	64.9 (0.1)
HSPC-Chol-PEG ₂₀₀₀	24	111.7 (1.1)	0.064 (0.01)	-17.3 (3.9)	72.8 (0.01)

HSPC, soy hydrogenated L- α -phosphatidylcholine; **ED**, Encapsulated drug.